Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports

Executive Summary

The first round of third-quarter earnings reports for big pharmas quietly featured news about drug discontinuations and failures.

Advertisement

Related Content

Roche's Post-Avastin Strategy Stumbles As Vanucizumab Fails In Phase II
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
Bristol's Sale Of HIV Pipeline To ViiV Signals Tightened Focus
Biogen's S1P Modulator License – A Good Deal Done Too Late?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel